Snopes tried to discredit research as a "rumor" when journalist received early results from conference call between researchers and study participants. Spike still detectable in some participants ...

HOSPITALS in England have been hit by a storm of norovirus infections, with cases reaching a record high. As well as bouts of ...

In the dark days of the coronavirus pandemic, Moderna (NASDAQ: MRNA) was a ray of light in more ways than one. The healthcare company's innovative Spikevax was one of the go-to vaccines that sped to ...

Nanoparticle characterization is vital for mRNA vaccine efficacy, ensuring safety and regulatory compliance in the ...

We recently published a list of 10 Firms Kick Off Shortened Trading Week With Impressive Gains. In this article, we are going ...

UBS lowered the firm’s price target on Moderna (MRNA) to $78 from $96 and keeps a Buy rating on the shares. UBS believes Moderna’s oncology ...

The FDA is mired in uncertainty with some staffers losing their jobs over the weekend and more potentially to come, vaccines ...

Moderna, Inc. (NASDAQ:MRNA – Get Free Report) was the recipient of unusually large options trading on Tuesday. Stock investors bought 179,268 call options on the company. This represents an increase ...

The article " Moderna: A Generational Opportunity for Investors in 2025 " first appeared on MarketBeat.

Fintel reports that on February 18, 2025, Barclays downgraded their outlook for Moderna (NasdaqGS:MRNA) from Overweight to ...

EPS estimates but beats revenue expectations. Barclays downgrades stock, citing COVID demand decline and RSV uptake ...